RxDoctor Payments Data

Kyle Machynia

Physician Assistant · Stateline, NVNPI 1851848956

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $71,916 of the $119,020 with a category attached, or 60.4%. 30 manufacturers reported payments, led by Johnson & Johnson at 52.9% of the total. 2025 is the largest year on record at $61,224, more than ten times the $2,286 reported in 2021. Among physician assistant clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$119,020in general payments, 2019–2025

Across 1,040 payments — averaging $114.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$63K
  • Galderma Laboratories, L.p.$17K
  • AbbVie$13K
  • Lilly USA, LLC$6K
  • Sanofi$4K
  • Ortho Dermatologics, A Division Of Bausch Health US, LLC$2K
  • plus $13K from 24 others

What the payments were for

  • Consulting fees$8,5517%
  • Speaking & faculty fees$71,91660%
  • Travel & lodging$11,44310%
  • Food & beverage$26,23522%
  • Education$8751%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$119,020 in reported general payments places this provider in the 95th percentile of 881 physician assistant providers in Nevada.

See all physician assistant providers in Nevada

Medicare billing

Part B allowed, 2024
$338,897
Medicare patients
750
Services billed
6,858

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab60$230,102
Taltz AutoinjectorIxekizumab25$204,596
Ketoconazole186$3,306
Triamcinolone Acetonide197$2,893
Doxycycline Hyclate127$2,022
Fluorouracil26$1,701
Tacrolimus25$1,399
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc46$851
Clobetasol Propionate16$830
Mometasone Furoate45$782
ValacyclovirValacyclovir Hcl33$764
Ciclopirox27$721
Clindamycin Phosphate17$459
Econazole Nitrate19$447
Cephalexin67$434

Paid to pharmacies, not to this prescriber.

Other physician assistant in Stateline

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →